This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

MarketVIEW: Dengue Vaccines

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MarketVIEW: Dengue vaccines

http://www.reportlinker.com/p0961686/MarketVIEW-Dengue-vaccines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Dengue fever (DF) is a mosquito-borne disease (Aedes) which can affect two fifths of the world's population. DF infection has a wide spectrum of symptoms that range from a mild febrile illness to severe outcomes, even death as observed in dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). Importantly, of the 22,000 estimated deaths per year, the large majority are in children (< 15yrs) where no specific treatment is available.

This MarketVIEW product forecasts the potential commercial value of dengue fever vaccine(s) across endemic and travelers markets to 2030. The model(s) contain value ($ m) and volume (mio doses) predictions for endemic countries in all age segments in both the public and private sector. LO and HI forecast scenarios which include expected demand from country selected catch-up campaigns are also detailed along with discussion of development considerations of the ideal dengue vaccine(s) in light of current pipeline candidates.

THIS PRODUCT IS TWO EXECUTIVE PRESENTATIONS + TWO MODELS 

Contents – Summary presentation (MS PowerPoint based)Author's noteExecutive SummaryCommercial model – key outputsSummary for total number of CDI cases (theoretical and treated) in Emerging + ROW region2020 Snapshot CDI cases (theoretical)Deploying C.diff vaccines: primary prevention (PX)C.diff vaccines: three potential markets modelledPX indication (community) – total predicted demand (doses 000s)PX indication (community) – total available market ($ USD 000s)PX indication (hospital admission) – total available market ($ USD 000s)TX indication (hospital) – total predicted demand (doses 000s)TX indication (hospital) – total available market ($ USD 000s)C.diff vaccines: total commercial summary (peak)C.diff vaccines – key model assumptionsC.diff vaccines – countries included in modelCommunity prophylaxis – major model assumptionsPrevention of CDI recurrences (TX) – major model assumptionsHospital prophylaxis – major model assumptionsPrimary research – summary of findingsC.diff (CDI) situation analysisPrimary research respondentsExpert viewpoints: nosocomial infections in generalExpert viewpoints: major pathogensExpert viewpoints: reporting surveillanceBrazil: National Health Surveillance Agency (ANVISA) Mexico: National Health Surveillance Agency (SALUD)Expert viewpoints: nosocomial infections – incidence estimatesExpert viewpoints: awareness of Clostridium difficileExpert viewpoints: is CDI a growing problem?Expert viewpoints: test for Clostridium difficileExpert viewpoints: C.diff molecular epidemiologyC.diff as a % of nosocomial diarrhea – Emerging markets/ROW regionExpert viewpoints: treating CDICountry environment factors contributing to CDIExpert viewpoints: (use) misuse of antibioticsExpert viewpoints: role of hospitals (LOS)Expert viewpoints: elderly care/the role of nursing homesOther notable patient factorsExpert Reaction to C.diff R&D pipeline and vaccinesCDI pipeline: by estimated filing dateExpert viewpoints: CDI R&D pipeline (all)Expert viewpoints: C.diff vaccines – general commentsExpert viewpoints: deploying C.diff vaccinesExpert viewpoints: funding C.diff vaccinesBack-up and source materialCDI – Western marketsDefinition of at-risk population (community vaccination)About VacZine AnalyticsDisclaimerPAGES: 60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model (MS Excel-based)Title sheetCHARTS (PX) comm.CHARTS (PX) hospCHARTS (TX)CHARTS (Epi)Val/Vol summary (PX comm)Val/Vol summary (PX hosp)Val/Vol summary (TX)Vaccine pricing forecastEpi summary – CDIProphylaxis (hosp admission)All admissions (>65 yrs)Emer admissions (>65yrs)Elect admissions (>65yrs)PX > 65yrs (comm) and TX (RD – first line)BrazilRussiaIndiaChinaArgentinaChileColumbiaVenezuelaTurkeySaudi ArabiaPolandCzech RepublicSlovakiaHungarySouth AfricaMalaysiaSingaporeIndonesiaPhilippinesThailandSouth KoreaSource materialNosocomial diarrhea (CDIFF)Hospital admissions forecastHospital beds – admissionsChina – hospital statisticsBrazil – hospital statisticsHospital beds (historical)Hospital discharges (historical)Population database (all ages)Population database (65 – 90 yrs)Hospital admission breakdown by typeBack-pageWORKSHEETS: ~65

To order this report:: MarketVIEW: Dengue vaccines



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs